Chronic kidney disease (CKD) is common and associated with a wide range of adverse outcomes. Two biomarkers, serum creatinine and albuminuria, provide the mainstay for staging and risk assessment for the majority of CKD patients. Both clinical trials and clinical care are hampered by the limitations of these markers and could benefit substantially from discovery and validation of additional markers. In reponse to the RFA, """"""""CKD Biomarker Discovery and Validation Consortium"""""""", we propose an innovative project that combines breakthrough methods for biomarker discovery with rigorous epidemiological, statistical and clinical chemistry expertise applied with a deep knowledge of four extremely well characterized cohorts.
Aim 1 : Biomarker Discovery. 1 .A. De novo discovery of serum filtration markers for CKD staging. State of the art proteomic discovery methods will identify proteins with >2x elevation from baseline to follow-up in stored serum of AASK participants whose measured GFR declined from >60 to <30 ml/min/1.73m2 or 2x their serum creatinine. 1 .B. Targeted discovery of urine and serum markers of damage for CKD progression. Absolute quantiation mass spectrometry methods will tests 15 of the most promising urine and serum markers in their ability to distinguish 100 cases with rapid CKD progression to EBRD from 100 controls with similar baseline measured GFR which remained stable from the AASK and MDRD Studies. 1 .C. Verification of the most promising markers from 1 .A. and 1 .B in a larger sample size Aim 2: Biomarker Validation: We will test the most promosing biomarkers identified in aim 1 and through by the consortium in their ability to estimate kidney function and risk of CKD progression in the entire AASK and MDRD Study population and case-control studies of progressive CKD in ARIC and a sample of NHANES. Our studies are guided by extensive experience in nephrology, biostatistics, epidemiology, proteomics, clinical chemistry, collaborative studies, recent pilot studies of novel markers for GFR estimation and genomic discoveries of relevant pathways for AKI and CKD.
Chronic kidney disease is common and usually stages by blood and urine markers. Currently serum creatinine and urinary albumin at the most widely used biomarkers for staging and prognosis of patients with chronic kidney disease. We propose to join a consortium whose goal is to discover and validate additional markers which will improve patient care and faciliate research in chronic kidney disease.
| Hu, Jiun-Ruey; Coresh, Josef; Inker, Lesley A et al. (2018) Serum metabolites are associated with all-cause mortality in chronic kidney disease. Kidney Int 94:381-389 |
| Rebholz, Casey M; Yu, Bing; Zheng, Zihe et al. (2018) Serum metabolomic profile of incident diabetes. Diabetologia 61:1046-1054 |
| Rebholz, Casey M; Selvin, Elizabeth; Liang, Menglu et al. (2018) Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. Kidney Int 93:252-259 |
| Luo, Shengyuan; Coresh, Josef; Tin, Adrienne et al. (2018) Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD. Clin J Am Soc Nephrol 13:1013-1021 |
| Grams, Morgan E; Shafi, Tariq; Rhee, Eugene P (2018) Metabolomics Research in Chronic Kidney Disease. J Am Soc Nephrol 29:1588-1590 |
| Rebholz, Casey M; Inker, Lesley A; Chen, Yuan et al. (2017) Risk of ESRD and Mortality Associated With Change in Filtration Markers. Am J Kidney Dis 70:551-560 |
| Inker, Lesley A; Coresh, Josef; Sang, Yingying et al. (2017) Filtration Markers as Predictors of ESRD and Mortality: Individual Participant Data Meta-Analysis. Clin J Am Soc Nephrol 12:69-78 |
| Wheelock, Kevin M; Cai, Jian; Looker, Helen C et al. (2017) Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus. PLoS One 12:e0180964 |
| Grams, Morgan E; Tin, Adrienne; Rebholz, Casey M et al. (2017) Metabolomic Alterations Associated with Cause of CKD. Clin J Am Soc Nephrol 12:1787-1794 |
| Hsu, Chi-Yuan; Xie, Dawei; Waikar, Sushrut S et al. (2017) Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression. Kidney Int 91:196-203 |
Showing the most recent 10 out of 31 publications
